Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Skyworks Solutions Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Skyworks Solutions Inc trades at $59.47 (market cap $8.99B). The key difference: Skyworks Solutions Inc is far larger — about 2× ACADIA Pharmaceuticals Inc.'s market cap, and Skyworks Solutions Inc pays a 4.75% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SWKS | |
|---|---|---|
Market Cap | $4.49B | $8.99B |
Sector | Health | Technology |
52-Week High | $28.06 | $83.40 |
52-Week Low | $20.06 | $52.50 |
Enterprise Value | $3.69B | $8.76B |
Dividend Yield | — | 4.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Skyworks Solutions (SWKS) trades at $59.76, down 4.48% on the day, with a bearish technical signal despite recent earnings beats. The company shows declining revenue and net income margins over recent years, though profitability metrics like gross margin remain solid at 41.08%. Recent news highlights product launches in EV and AI infrastructure alongside ongoing legal investigations into corporate governance.
The outlook is mixed: strong analyst buy consensus (60%) and a $72.56 price target suggest upside, but declining cash flow and revenue trends pose risks. Investment opportunity lies in market diversification and new tech segments, balanced against margin pressure and legal overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
